<DOC>
	<DOCNO>NCT01725542</DOCNO>
	<brief_summary>Evaluation efficacy tolerance QUadruple therapy Asunaprevir , Daclatasvir , Ribavirin pegylated Interferon alpha-2a , HIV-HCV genotype 1 4 coinfected patient previously null responder standard Pegylated Interferon -Ribavirin regimen . The proportion patient present cirrhosis ( define METAVIR F4 score liver biopsy and/or hepatic impulse elastometry ≥ 15 kPa ) limit 50 % patient include</brief_summary>
	<brief_title>Pilot Study Assess Efficacy Tolerance QUadruple Therapy Treat HIV-HCV Coinfected Patients Previously Null Responders</brief_title>
	<detailed_description>The clinical trial multi-center , national , Phase 2 , open-label , single-arm . Primary objective estimate Sustained Virological Response rate ( SVR ) 12 week 24 week treatment quadruple therapy combine Asunaprevir , Daclatasvir , Ribavirin Pegylated Interferon alpha-2a HIV-HCV genotype 1 4 coinfected patient previously null responder Pegylated Interferon -Ribavirin standard regimen . Estimated enrolment 65 patient enrolment period ( 9 month ) . The first 12 patient include Raltegravir , Emtricitabine Tenofovir participate pharmacological sub-study . Schedule assessment : Evaluation inclusion criterion : 4 8 week Anti-HCV treatment : 28 week ( short accord futility rule ) Follow : 24 week follow end treatment</detailed_description>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult ≥18 year confirm HIV1 2 infection Infection HCV genotype 1 4 , confirm detectable HCVRNA ≥ 1000 IU/mL screen . Null responders previous treatment Peginterferon Ribavirin , define fall le 2 log10 IU/ml HCVRNA baseline week 12 . Stable antiretroviral treatment &gt; 1 month screen contain follow drug : Raltegravir , Enfuvirtide , TenofovirEmtricitabine , AbacavirLamivudine . CD4 &gt; 200 /mm3 &gt; 15 % screen HIVRNA &lt; 400 copies/mL ≥ 3 month screen Any liver fibrosis stage , assessment presence cirrhosis screening : previous liver biopsy exhibit cirrhosis lesion ( METAVIR F4 ) , and/or significant liver biopsy ( cumulative length ≥ 15 mm ≥ 6 portal space ) , within 18 month end last HCV treatment , and/or significant reliable liver stiffness assessment ( Fibroscan® ) within 6 month ( least 10 measure IQR le 25 % mean value success rate least 80 % ) cirrhosis define METAVIR score F4 liver biopsy and/or liver elastometry ≥ 15 kPa proportion patient cirrhosis ( METAVIR F4 ) limit 50 % patient . Body weight ≥ 40 kg ≤125 kg Male patient , female patient childbearing potential heterosexual partner must use adequate contraception 1 month initiation treatment 7 month follow end treatment men 4 month follow end treatment woman . Informed sign consent For participate patient , inform sign consent pharmacokinetic substudy Patients affiliate National Health Insurance cover Universal Medical Coverage For first 12 patient include ( participate pharmacological substudy ) : stable antiretroviral treatment &gt; 1 month screening , Raltegravir+ Emtricitabine+ Tenofovir CHILD B C cirrhosis , past history decompensated cirrhosis . Patients CHILD A cirrhosis must demonstrate absence significant oesophageal varix ( Stages 23 ) upper gastrointestinal endoscopy ≤ 12 month Positive HBs antigenemia HBV DNA &gt; 1000 IU/ml ( ( positive AgHBs HBV DNA ≤ 1000 IU/mL , patient include provide treated Ténofovir ) Pregnant woman , breastfeed woman Refusal adequate contraception Contraindication Ribavirin , include hypersensitivity reaction Ribavirin Contraindication Peginterferon , include psychiatric contraindication . Patients significant psychiatric past history , notably severe depression require hospitalization suicide attempt , include unless undergo psychiatric evaluation obtain specific authorization use interferon . Premature discontinuation ( first six month ) previous HCV treatment toxicity . Patients stop previous treatment severe anaemia neutropenia enter study erythropoietin granulocyte growth factor use previous treatment Previous HCV therapy include HCV NS3 protease inhibitor Severe preexist cardiac pulmonary disease History organ transplant Acute CDC stage C opportunistic infection occur within previouW6 month Any active malignant disease include hepatocellular carcinoma specific assessment require screen Alcohol intake may represent obstacle participation subject study Substance abuse may represent obstacle participation subject study . Stabilized patient included substitution program participate study Patients previous observance problem unable observe study procedure Participation another clinical trial within previous 30 day Haemoglobin &lt; 90 g/L Platelets &lt; 50 000 /mm3 Neutrophil count &lt; 750 /mm3 Renal insufficiency define estimate Glomerular Filtration Rate &lt; 50 mL/mn ( MDRD equation ) Absence antiretroviral treatment antiretroviral treatment different authorized combination Associated medication likely interfere study drug CPY3A4 inducer ( rifampin , Millepertuis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>HCV-HIV Co-Infection</keyword>
	<keyword>Quadruple therapy</keyword>
	<keyword>null responder standard Pegylated interferon/Ribavirin regimen</keyword>
</DOC>